Mudar Patherya’s previous stock recommen dations have yielded huge gains. He has now recommended four top-quality stocks which are presently languishing at the bottom of the barrel. If the stocks get their act in order, investors will be able to effortlessly reap multibagger gains, he says
Adi Godrej, the visionary industrialist, has made the sensational revelation that Temasek, the private equity giant, will cause value unlocking to happen to one of Vijay Kedia’s favourite stocks. This will generate mega gains for all concerned
The experts at the ValuePickr forum have not only given a clean chit to a small-cap stock but have foreseen that mega gains can be harvested from the stock. We need to stay alert to the situation because there is a chance for us to pocket a few bucks as well
Kshitij Anand of ET has spoken to leading stock market experts and collated their views on the top ten stocks that investors should buy in 2017 for multibagger gains
Mudar Patherya has put a little known small-cap on the center stage and confidently predicted that it will be “the next Ajanta Pharma”. The stock boasts of impeccable credentials and is well on the way to proving Mudar’s prediction correct
Eminent technical analysis experts have expressed the unanimous opinion that a small-cap Pharma stock, which is a certified potential 100-bagger, is in a “perfectly uptrending” position and will provide quick-fire gains in the short-term
Daljeet Kohli is known to be a master of Pharma stocks while Porinju Veliyath is lauded for his expertise in harvesting mega gains from underdog stocks. Both have homed in on a mid-cap Pharma stock but expressed contrary views about its future prospects
Today, when panic-stricken investors were running helter-skelter due to NAMO’s knee-jerk crackdown over their favourite stocks, the Gurus had a benign smile. Their immense wisdom had spared them once again from calamity & carnage!
A mid-cap Pharma stock has become the favourite of several ace stock pickers because of it’s dominance in the market place, high RoEs, quality management and reasonable valuations. The stock is also proclaimed as a potential 100-bagger stock. Daljeet Kohli claims the stock is a good buy now because it is “ripe for re-rating“
Forbes India’s much-awaited stock recommen dations for 2016 are finally here. The recommendations do not disappoint. Each stock is a powerhouse capable of pumping out hefty returns year after year
Recent Comments